FASTinov’s Cutting-Edge Technology to be Introduced in Routine into a Prestigious Oncology Hospital – IPO Porto

FASTinov’s Cutting-Edge Technology to be Introduced in Routine into a Prestigious Oncology Hospital – IPO Porto

September 30th 2023

(Porto, Portugal) – FASTinov, the global leader in rapid antimicrobial susceptibility testing (AST), is proud to announce that a prestigious oncology hospital has chosen to integrate its cutting-edge technology into its healthcare infrastructure. Following a thorough evaluation process, IPO Porto has recognized the transformative potential of FASTinov’s AST solution in serving the needs of oncology patients.

This strategic partnership marks a significant milestone for both FASTinov and the oncology hospital, as they join forces to enhance patient care and treatment outcomes. By integrating FASTinov’s technology, the hospital aims to streamline and optimize antimicrobial susceptibility testing processes, ensuring timely and targeted interventions for oncology patients.

Nuno Afonso, CEO of FASTinov, expressed his enthusiasm for this collaboration, stating,
“We are honoured to partner with such a renowned oncology hospital. This integration underscores the value and impact of our technology in diverse healthcare settings, and we are committed to supporting the hospital in its mission to deliver exceptional care to oncology patients.”

The decision to integrate FASTinov’s technology reflects the hospital’s commitment to staying at the forefront of medical innovation and providing the highest standard of care to its patients. By leveraging FASTinov’s rapid AST solution, healthcare providers at the oncology hospital will have access to actionable insights that enable personalized treatment strategies, ultimately improving patient outcomes and quality of life.

Dr. Cidália Pina Vaz, Chief Scientific Officer of FASTinov, emphasized the importance of this partnership in advancing oncology care.
“We are excited to collaborate with the oncology hospital to integrate our technology seamlessly into their workflow. This partnership represents a significant step forward in the fight against infection in cancer patients, as we work together to empower healthcare providers with the tools they need to make informed treatment decisions on a timely manner.”

As FASTinov continues to expand its presence in diverse healthcare settings, this partnership with IPO Porto reaffirms its commitment to revolutionizing patient care through innovative technology and collaborative partnerships.

About FASTinov

FASTinov is a leading innovator in rapid antimicrobial susceptibility testing, dedicated to revolutionizing patient care in sepsis contexts. With a mission to provide actionable same-shift results, FASTinov’s cutting-edge technology offers healthcare professionals unprecedented insights for targeted treatment decisions.

Share with friends